Researchers have identified an antibody against an inflammatory migraine inducing molecule.
The Phase 3 trial was conducted by Stephen D Silberstein, at the Thomas Jefferson University in the US.
Evidence and results?
The antibody, called Fremanezumab, reduced the migraines by 50% in a study. It is being investigated further as a prevention medicine, with the study funded by Teva Pharmaceuticals. Teva, hopes to get a FDA approval in 2018.